FDA Warns P&G Over Vicks Products With Vitamin C

 

SILVER SPRING, Md. (AP) — The U.S. Food and Drug Administration sent a warning letter Friday to Procter & Gamble Co. saying the company was illegally marketing two Vicks cold and flu medicines containing vitamin C.

The FDA said the single-dose combinations of drug and dietary ingredients in Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C cannot be marketed legally because they have not been proven safe and effective.

The agency also said it had previously determined that there was insufficient data to show vitamin C is safe and effective in preventing or treating the common cold.

Earlier this month the agency issued a similar warning letter but then quickly retracted it. FDA spokesman Christopher Kelly said Friday the letter was "issued prematurely — it had not completed our internal clearance process."

The FDA said it allows some over-the-counter drugs to be marketed without agency approval, but that the two Vicks products did not comply with its rules and first must be evaluated and approved under the FDA's new drug approval process.

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,801.23 1,342.64 2,903.88 19.69
Oil *
117.67
DOWN
89.23
DOWN
9.31
DOWN
23.35
DOWN
0.78
10 Yr
1.97%
SPDR Gold
167.14
-0.69%
-0.69%
-0.80%
-3.81%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet